STOCK TITAN

Olink announces change of date for Annual General Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Olink Holding AB reschedules its 2024 Annual General Meeting to April 19th, 2024, in Uppsala, Sweden.
Positive
  • None.
Negative
  • None.

UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.

About Olink
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. Olink was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.

IR contact
David Deuchler, CFA
Gilmartin Group
olink@gilmartinir.com  

Media contact
Michael B. Gonzales
VP Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com


FAQ

When is Olink Holding AB's 2024 Annual General Meeting scheduled?

Olink Holding AB's 2024 Annual General Meeting is rescheduled to April 19th, 2024.

Where will Olink Holding AB's 2024 Annual General Meeting take place?

Olink Holding AB's 2024 Annual General Meeting will be held in Uppsala, Sweden.

Olink Holding AB (publ)

NASDAQ:OLK

OLK Rankings

OLK Latest News

OLK Stock Data

2.99B
40.67M
66.62%
34.6%
1.87%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
Uppsala

About OLK

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.